Injectable nanoparticulate olanzapine formulations
AssigneeElan Pharma International Limited
InventorsStephen B. Ruddy, David Czekai, Gary Liversidge, Scott A. Jenkins, Elaine M. Liversidge
Life of this patent
Estimating the term…
Abstract
Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine.
Claims28
An injectable depot composition comprising:
- (a) particles of olanzapine its salts, hydrates, solvates, polymorphs, co-crystalline, prodrugs, or analogues thereof, the particles having an effective average particle size of less than 5000 nm;
- (b) at least one surface stabilizer adsorbed on the surface of the particles;
- and
- (c) a pharmaceutically acceptable carrier,
- wherein the injectable depot has a therapeutic efficacy of about one week or greater.
A method of making an injectable nanoparticulate olanzapine composition that produces an intramuscular depot upon administration comprising:
- contacting particles of olanzapine or a salt thereof with at least one surface stabilizer for a time and under conditions sufficient to provide a olanzapine composition having an effective average particle size that results in a therapeutic efficacy of about one week or greater.
A method for the treatment of a subject for disorders of the central nervous system comprising administering to the subject an effective amount of an injectable composition comprising:
- (a) olanzapine nanoparticles having an effective average particle size that results in a therapeutic efficacy of about one week or greater;
- (b) at least one surface stabilizer;
- (c) at least one pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.